Retatrutide: Triple Incretin Receptor Agonism in Preclinical Research

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide engineered as a triple agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR) [1]. Its design integrates a C20 fatty diacid moiety for albumin binding and a modified backbone that produces balanced — but tunable — agonism across all three receptors, extending the “polyagonist” concept first established with dual GIP/GLP-1 compounds.

In recombinant HEK293 cells expressing each receptor individually, Retatrutide produced full agonist responses at GLP-1R and GCGR with sub-nanomolar potency and partial agonism at GIPR [1]. The inclusion of glucagon receptor activity is mechanistically relevant because GCGR engagement increases hepatic lipid oxidation and energy expenditure — pharmacology distinct from incretin-only compounds [2].

In diet-induced obese mice, chronic Retatrutide dosing produced greater reductions in adipose mass and food intake than matched-exposure Semaglutide or Tirzepatide comparators [3]. Indirect calorimetry showed increased energy expenditure attributable to the GCGR component, with hepatic triglyceride content reduced in treated animals on standard histology [3].

Mechanistic dissection using receptor-knockout mice has confirmed contributions from each receptor. The body-weight effect is partially attenuated in single-receptor knockouts and substantially reduced in double-knockout backgrounds [4]. In cultured rodent hepatocytes, the peptide increased β-oxidation gene expression — consistent with GCGR-mediated hepatic actions [4].

Cardiovascular and renal preclinical work remains an active area, with rodent models examining effects on cardiac hypertrophy markers and renal hemodynamics under high-fat-diet challenge [5].

Frontier Peptide Labs supplies a research-grade Retatrutide (GLP3) vial with third-party HPLC purity verification for laboratory research use only.

References

1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013
2. Müller TD, et al. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721-766. DOI: 10.1152/physrev.00025.2016
3. Urva S, et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. 2022;400(10366):1869-1881. DOI: 10.1016/S0140-6736(22)02033-5
4. Knerr PJ, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. DOI: 10.1016/j.molmet.2022.101533
5. Finan B, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. DOI: 10.1038/nm.3761